thiazoles has been researched along with Urinary Incontinence in 49 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (6.12) | 29.6817 |
| 2010's | 36 (73.47) | 24.3611 |
| 2020's | 10 (20.41) | 2.80 |
| Authors | Studies |
|---|---|
| Ariman, A; Çulha, MG; Merder, E | 1 |
| Yamanishi, T | 1 |
| Kuroishi, K; Mishima, Y; Takahashi, S; Ukai, M | 1 |
| Brubaker, L; Halverson, T; Mueller, ER; Wolfe, AJ | 1 |
| Dmochowski, R; Gleicher, S; Reynolds, WS; Sebesta, EM | 1 |
| Becher, K; Bojack, B; Ege, S; Kirschner-Hermanns, R; von der Heide, S; Wiedemann, A | 1 |
| Fuse, M; Kaga, K; Kageyama, S; Sakata, K; Tokunaga, S; Yamanishi, T; Yokoyama, T | 1 |
| Gibson, W; Makhani, A; Thake, M | 1 |
| Herschorn, S; Kristy, RM; Schermer, CR; Staskin, D; Wagg, A | 1 |
| Chang, YS; Choo, MS; Kim, JC; Ko, KJ; Lee, KS | 1 |
| Champilomatis, I; Dimitriadis, F; Filiponi, M; Kaltsas, A; Mamoulakis, C; Paliouras, A; Sofikitis, N; Takenaka, A; Tsounapi, P; Zachariou, A | 1 |
| Abrams, P; Arlandis, S; Chapple, CR; Herschorn, S; Lee, KS; Mitcheson, D; Paireddy, A; Ridder, A; Robinson, D; Stoelzel, M; van Maanen, R | 1 |
| Kato, D; Tabuchi, H; Uno, S | 1 |
| Choudhury, N; Drake, MJ; Gibson, W; Huang, M; MacDiarmid, S; Siddiqui, E; Stölzel, M | 1 |
| Baltogiannis, D; Dimitriadis, F; Filiponi, M; Giannakis, J; Sofikitis, N; Takenaka, A; Tsounapi, P; Zachariou, A | 1 |
| Kasyan, GR; Pushkar, DY; Sukhikh, SO | 1 |
| Filipe, TP; Marques, JG | 1 |
| Abrams, P; Al-Shukri, S; Chapple, C; Gratzke, C; Herschorn, S; Mueller, ER; Paireddy, A; Rechberger, T; Ridder, A; Robinson, D; Stoelzel, M; van Maanen, R; Yoon, SJ | 1 |
| Deeks, ED | 1 |
| Ikeda, S; Tajima, H; Yamanishi, T; Yamanishi, Y | 1 |
| Ethans, K; Hickling, D; McKibbon, M; Radomski, S; Welk, B | 1 |
| Kuo, HC; Liao, CH | 1 |
| Gotoh, M; Hamada, T; Homma, Y; Igawa, Y; Kakizaki, H; Kobayashi, A; Kuroishi, K; Nishizawa, O; Okitsu, A; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M | 1 |
| Abrams, P; Al-Shukri, S; Chapple, C; Gratzke, C; Herschorn, S; Mueller, ER; Rechberger, T; Robinson, D; Stoelzel, M; van Maanen, R; Yoon, SJ | 1 |
| Boerrigter, P; Bosman, B; Chapple, CR; Drogendijk, T; Dvorak, V; Radziszewski, P; Ridder, A; Van Der Putten-Slob, I; Van Kerrebroeck, P; Wyndaele, JJ; Yamaguchi, O | 1 |
| Angulo, JC; Blauwet, MB; Cambronero, J; Dorrepaal, C; Herschorn, S; Khullar, V; Martin, NE; Nitti, VW; Siddiqui, E; van Kerrebroeck, P | 1 |
| Bassi, P; Bientinesi, R; D'Agostino, D; Gulino, G; Racioppi, M; Sacco, E; Tienforti, D; Vittori, M | 1 |
| Auerbach, S; Blauwet, MB; Cardozo, L; Castro-Diaz, D; Nitti, VW; Siddiqui, E; Wagg, A | 1 |
| Kulik-Rechberger, B; Miotła, P; Rechberger, T; Wróbel, A | 1 |
| Blauwet, MB; Chapple, C; Frankel, J; Herschorn, S; Kaper, M; Khullar, V; Nitti, VW; Siddiqui, E | 1 |
| Ghezzi, F; Serati, M | 1 |
| Bu, SY; Cao, CX; Duan, X; Peng, CD; Wang, KJ; Wu, T | 1 |
| Becher, KF; Sieber, CC | 1 |
| Blauwet, MB; Castro-Diaz, D; Chapple, CR; Delgado-Herrera, L; Hakimi, Z; Lau, W; Mujais, S | 1 |
| Griebling, TL | 1 |
| Abrams, P; Kay, R; Martina, R; Ridder, A; van Maanen, R | 1 |
| Blais, AS; Bolduc, S; Genois, L; Moore, K; Nadeau, G | 1 |
| Arber, M; Fleetwood, K; Freemantle, N; Ginsberg, DA; Glanville, J; Khalaf, K; Loveman, C; McCool, R; Ni, Q | 1 |
| Athanasiou, S; Cambronero, J; Chapple, C; Drake, MJ; Esen, AA; Herholdt, C; Herschorn, S; Huang, M; MacDiarmid, S; Mitcheson, D; Saleem, T; Siddiqui, E; Stölzel, M | 1 |
| Al-Shukri, S; Barkin, J; Drake, MJ; Fianu-Jonasson, A; Grise, P; Hakimi, Z; Hemsted, C; Herschorn, S; Huang, M; MacDiarmid, S; Nazir, J; Saleem, T; Siddiqui, E; Stölzel, M | 1 |
| Sidaway, P | 1 |
| Campbell, NL; Klein, RW; Klein, TM; Ng, DB; Perk, S; Posta, LM; Wielage, RC; Yuran, T | 1 |
| Legrand, F; Moyson, J; Quackels, T; Roumeguère, T; Vanden Bossche, M | 1 |
| Baralatei, FT; Lauterbach, EC | 1 |
| Tyagi, P; Tyagi, V | 1 |
| Schapira, AH | 1 |
| Lazzeri, M | 1 |
13 review(s) available for thiazoles and Urinary Incontinence
| Article | Year |
|---|---|
Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient.
Topics: Acetanilides; Age Factors; Aged; Aged, 80 and over; Female; Humans; Lower Urinary Tract Symptoms; Nocturia; Patient Safety; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2020 |
[The place of mirabegron in clinical practice].
Topics: Acetanilides; Female; Humans; Male; Thiazoles; Urinary Bladder, Neurogenic; Urinary Incontinence | 2017 |
Mirabegron: A Review in Overactive Bladder Syndrome.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Female; Humans; Male; Muscarinic Antagonists; Signal Transduction; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2018 |
Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.
Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Cresols; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Muscarinic Antagonists; Phenylpropanolamine; Randomized Controlled Trials as Topic; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents; Young Adult | 2013 |
Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Humans; Receptors, Adrenergic, beta-3; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence; Urinary Tract; Urological Agents | 2014 |
The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Age Factors; Aged; Clinical Trials, Phase III as Topic; Humans; Randomized Controlled Trials as Topic; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2014 |
[The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist].
Topics: Acetanilides; Adrenergic beta-3 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence | 2014 |
The role of mirabegron in overactive bladder: a systematic review and meta-analysis.
Topics: Acetanilides; Benzhydryl Compounds; Cresols; Humans; Muscarinic Antagonists; Odds Ratio; Phenylpropanolamine; Prospective Studies; Research Design; Software; Surveys and Questionnaires; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2014 |
[Urinary incontinence: what's new in therapy?].
Topics: Acetanilides; Administration, Intravesical; Aged; Behavior Therapy; Botulinum Toxins, Type A; Cholinergic Antagonists; Combined Modality Therapy; Cooperative Behavior; Female; Humans; Interdisciplinary Communication; Male; Thiazoles; Urinary Bladder; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urinary Incontinence | 2015 |
Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison.
Topics: Acetanilides; Botulinum Toxins, Type A; Humans; Nocturia; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2016 |
[Efficacy and safety of available therapies in the management of idiopathic overactive bladder: A systematic review of the literature].
Topics: Acetanilides; Botulinum Toxins, Type A; Cholinergic Antagonists; Humans; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2017 |
Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Rats; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urination Disorders | 2010 |
Present and future drug treatment for Parkinson's disease.
Topics: Benzothiazoles; Corpus Striatum; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Humans; Indans; Indoles; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Pramipexole; Psychomotor Performance; Sexual Dysfunction, Physiological; Sleep Wake Disorders; Substantia Nigra; Thiazoles; Urinary Incontinence | 2005 |
16 trial(s) available for thiazoles and Urinary Incontinence
| Article | Year |
|---|---|
Efficacy of mirabegron, a β
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Double-Blind Method; Female; Humans; Japan; Muscarinic Antagonists; Quality of Life; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2022 |
A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study).
Topics: Acetanilides; Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tadalafil; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2020 |
Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Age Factors; Aged; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Female; Headache; Humans; Male; Middle Aged; Severity of Illness Index; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2020 |
Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
Topics: Acetanilides; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Internationality; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Risk Assessment; Single-Blind Method; Solifenacin Succinate; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2017 |
Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
Topics: Acetanilides; Aged; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Muscarinic Antagonists; Single-Blind Method; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2017 |
Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
Topics: Acetanilides; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Solifenacin Succinate; Symptom Assessment; Thiazoles; Time; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2018 |
A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction.
Topics: Acetanilides; Adult; Aged; Canada; Double-Blind Method; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Pilot Projects; Spinal Cord Injuries; Thiazoles; Treatment Outcome; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urinary Incontinence; Urodynamics | 2018 |
Mirabegron escalation to 50 mg further improves daily urgency and urgency urinary incontinence in Asian patients with overactive bladder.
Topics: Acetanilides; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Male; Middle Aged; Taiwan; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2019 |
Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Benzilates; Blood Pressure; Constipation; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imidazoles; Japan; Male; Middle Aged; Muscarinic Antagonists; Nasopharyngitis; Severity of Illness Index; Solifenacin Succinate; Thiazoles; Time Factors; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Xerostomia | 2019 |
Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study.
Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents; Young Adult | 2019 |
A phase II dose-ranging study of mirabegron in patients with overactive bladder.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Incidence; Internationality; Male; Middle Aged; Quality of Life; Single-Blind Method; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2013 |
Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Severity of Illness Index; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence; Urination | 2015 |
The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials.
Topics: Acetanilides; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Patient Satisfaction; Quality of Life; Surveys and Questionnaires; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2015 |
A clinical perspective on the analysis and presentation of the number of incontinence episodes following treatment for OAB.
Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2016 |
Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
Topics: Acetanilides; Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Retreatment; Solifenacin Succinate; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2016 |
Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Solifenacin Succinate; Thiazoles; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urodynamics; Young Adult | 2016 |
20 other study(ies) available for thiazoles and Urinary Incontinence
| Article | Year |
|---|---|
The effect of Mirabegron and Duloxetine combination in mixed-type urinary incontinence treatment.
Topics: Acetanilides; Double-Blind Method; Duloxetine Hydrochloride; Humans; Retrospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2021 |
Editorial Comment to Efficacy of mirabegron, a β
Topics: Acetanilides; Double-Blind Method; Female; Humans; Japan; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence | 2022 |
Symptom improvement with mirabegron treatment is associated with urobiome changes in adult women.
Topics: Acetanilides; Adult; Aged; Female; Humans; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2022 |
Vibegron for the treatment of overactive bladder: a comprehensive update.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Muscarinic Antagonists; Pyrimidinones; Pyrrolidines; Receptors, Adrenergic, beta-3; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2022 |
[Urinary incontinence in geriatric patients: pharmacological Therapy].
Topics: Acetanilides; Aged; Botulinum Toxins; Cholinesterase Inhibitors; Duloxetine Hydrochloride; Female; Frail Elderly; Humans; Male; Muscarinic Antagonists; Practice Guidelines as Topic; Societies, Medical; Thiazoles; Urinary Incontinence | 2019 |
A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study).
Topics: Acetanilides; Aged; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Prospective Studies; Retreatment; Surveys and Questionnaires; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2020 |
Mirabegron Alleviates the Degree of Burden Experienced by Caregivers of Older Females with Mixed or Urge Incontinence: A Prospective Study.
Topics: Acetanilides; Aged; Caregiver Burden; Caregivers; Female; Humans; Outcome Assessment, Health Care; Pilot Projects; Quality of Life; Surveys and Questionnaires; Thiazoles; Urinary Incontinence; Urological Agents | 2021 |
Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: Interim (1-year) report from a Japanese post-marketing surveillance study.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Long-Term Care; Male; Middle Aged; Product Surveillance, Postmarketing; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2019 |
Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Antidiuretic Agents; Deamino Arginine Vasopressin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscarinic Antagonists; Retreatment; Solifenacin Succinate; Thiazoles; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urinary Incontinence; Urination | 2017 |
Pleurothotonus (Pisa syndrome) Induced by an Association of Clozapine and Mirabegron.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Antipsychotic Agents; Bipolar Disorder; Clozapine; Drug Interactions; Dystonia; Female; Humans; Middle Aged; Posture; Thiazoles; Urinary Incontinence | 2018 |
Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment?
Topics: Acetanilides; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Costs; Humans; Japan; Markov Chains; Muscarinic Antagonists; Quality of Life; Severity of Illness Index; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2018 |
New treatments for incontinence. Find out which of the latest therapies are worth trying.
Topics: Acetanilides; Botulinum Toxins, Type A; Humans; Mandelic Acids; Suburethral Slings; Thiazoles; Transdermal Patch; Urinary Incontinence; Urological Agents | 2014 |
Severity of symptoms of overactive bladder: a predictor of success and of failure.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Female; Humans; Male; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence | 2015 |
Re: The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2015 |
Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder.
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Child; Female; Humans; Male; Muscarinic Antagonists; Off-Label Use; Patient Satisfaction; Pilot Projects; Prospective Studies; Retreatment; Surveys and Questionnaires; Thiazoles; Treatment Failure; Urinary Bladder, Overactive; Urinary Incontinence | 2016 |
Incontinence: Adding mirabegron to solifenacin improves patient outcomes.
Topics: Acetanilides; Humans; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2016 |
Mirabegron: hypertension, stroke.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Humans; Hypertension; Stroke; Thiazoles; Urinary Incontinence | 2016 |
Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.
Topics: Acetanilides; Cost-Benefit Analysis; Economics, Pharmaceutical; Female; Humans; Male; Markov Chains; Medicare Part C; Muscarinic Antagonists; Thiazoles; United States; Urinary Bladder, Overactive; Urinary Incontinence; Urological Agents | 2016 |
Switching to duloxetine remits ziprasidone - associated urinary incontinence and improves neuropsychiatric behavior in dementia: possible relationship of incontinence to 5HT2 receptor blockade.
Topics: Aged, 80 and over; Alzheimer Disease; Dementia, Vascular; Duloxetine Hydrochloride; Humans; Male; Parkinsonian Disorders; Piperazines; Receptors, Serotonin, 5-HT2; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Thiazoles; Thiophenes; Urinary Incontinence | 2009 |
Editorial comment on: Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Aprepitant; Female; Humans; Morpholines; Pyrazoles; Receptors, Neurokinin-1; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urinary Incontinence; Urodynamics | 2009 |